RxDoctor Payments Data

Brian Renard

Cardiovascular Disease · Troy, MINPI 1609160415

Payments from drug & device makers

$41,657in general payments, 2019–2025

Across 89 payments — averaging $468.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$32K
  • Abbott$5K
  • Edwards Lifesciences$4K
  • Boston Scientific$414
  • Amgen$42
  • Amarin Pharma, Inc.$41
  • plus $98 from 6 others

What the payments were for

  • Grants$26,00062%
  • Travel & lodging$12,46630%
  • Food & beverage$3,1788%
  • Education$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$41,657 in reported general payments places this provider in the 80th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$253,933
Medicare patients
923
Services billed
2,284

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban376$491,052
XareltoRivaroxaban140$197,640
EntrestoSacubitril/Valsartan116$172,383
Repatha SureclickEvolocumab223$165,911
JardianceEmpagliflozin36$47,917
Praluent PenAlirocumab56$33,312
Ranolazine ErRanolazine84$10,397
BrilintaTicagrelor11$8,794
Atorvastatin Calcium545$8,648
Metoprolol Succinate395$8,119
Rosuvastatin Calcium405$7,171
Carvedilol324$5,242
ClopidogrelClopidogrel Bisulfate188$4,614
Ezetimibe161$4,471
Losartan Potassium253$3,779

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$25$491,052376 claims
NovartisEntresto$13$172,383116 claims
AstraZenecaBrilinta$14$8,79411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Troy

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →